Avoid Anti-HER2 Cancer Therapies During Pregnancy Avoid Anti-HER2 Cancer Therapies During Pregnancy
Women with HER2-positive breast cancer who receive HER2-targeted therapies during pregnancy face a higher risk for severe adverse outcomes to their fetus or newborn, new research indicates.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - November 29, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
The First Over-the-Counter Birth Control Pill Gets Official Approval
WASHINGTON (AP) — U.S. officials have approved the first over-the-counter birth control pill, which will let American women and girls buy contraceptive medication from the same aisle as aspirin and eyedrops.
The Food and Drug Administration said Thursday it cleared Perrigo’s once-a-day Opill to be sold without a prescription, making it the first such medication to be moved out from behind the pharmacy counter. The company won’t start shipping the pill until early next year, and there will be no age restrictions on sales.
Hormone-based pills have long been the most common form of birth control in the U.S.,...
Source: TIME: Health - July 13, 2023 Category: Consumer Health News Authors: MATTHEW PERRONE / AP Tags: Uncategorized Equality wire Source Type: news
Pausing Endocrine Therapy to Attempt Pregnancy Is Safe Pausing Endocrine Therapy to Attempt Pregnancy Is Safe
The POSITIVE trial provides strong evidence that women with HR-positive early breast cancer can safely interrupt endocrine therapy to try to become pregnant.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - May 5, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Temporary Interruption of Endocrine Therapy for Breast Cancer Safe
THURSDAY, May 4, 2023 -- Among select women with previous hormone receptor-positive early breast cancer, there is no increase in the short-term risk for breast cancer events with temporary interruption of endocrine therapy to attempt pregnancy,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 4, 2023 Category: Pharmaceuticals Source Type: news
Breast Cancer Survivors Can Safely Interrupt Therapy During Pregnancy: Study
WEDNESDAY, May 3, 2023 -- For young women who survive breast cancer, a new study offers some reassurance about pregnancy: Pausing hormonal therapy to have a baby does not raise the risk of a cancer recurrence, at least in the shorter term.
A trial... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - May 4, 2023 Category: General Medicine Source Type: news
ERLEADA ® (apalutamide), First-and-Only Next-Generation Androgen Receptor Inhibitor with Once-Daily, Single-Tablet Option, Now Available in the U.S.
HORSHAM, Pa., April 3, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the availability of an additional tablet strength of ERLEADA® (apalutamide) in the United States. The introduction of the 240mg tablet provides the first-and-only option for a once-daily, single-tablet Androgen Receptor Inhibitor (ARI) approved for the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC) and for the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC).With two strengths available, healthcare professionals will have the flexibility to...
Source: Johnson and Johnson - April 3, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
The Physical Toll Systemic Injustice Takes On the Body
The pathologists who performed Dr. Martin Luther King Jr.’s autopsy noted he had the heart of a 60 year old, although he was 39 when he died. His damaged heart was duly noted in the official record as a curiosity, but there was no question as to the cause of death: homicide; indeed, assassination. A racist hate crime.
But if we were to try to understand the poor condition of his heart, we might be flummoxed. Our general repertoire for understanding the early onset of heart disease points us to demographic and behavioral risk factors like poverty, low education, family breakdown, unhealthy diet, and little exercise. K...
Source: TIME: Health - March 28, 2023 Category: Consumer Health News Authors: Arline T. Geronimus Tags: Uncategorized freelance Race Source Type: news
All Types of Hormonal Birth Control Share a Slightly Increased Risk of Breast Cancer, Study Says
For people who want to prevent pregnancy, birth-control drugs come with an obvious reward. They also come with some small risks—including, for some forms, a slightly increased risk of breast cancer.
This has long been known about the most popular type: combined hormonal birth control, which is available in pill, patch, and ring form. These all contain both estrogen and progestin, a synthetic version of the naturally occurring reproductive hormone progesterone.
Less is known about the breast-cancer risks of progestin-only birth control, a type that’s growing in popularity because it only contains one hormone. B...
Source: TIME: Health - March 21, 2023 Category: Consumer Health News Authors: Haley Weiss Tags: Uncategorized Drugs healthscienceclimate Source Type: news
Janssen Data at ASCO GU Support Ambition to Transform Treatment of Prostate and Bladder Cancer Through Precision Medicine and Early Intervention
RARITAN, N.J., February 13, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced plans to present more than 20 abstracts featuring seven oncology therapies from its robust portfolio and pipeline at the annual American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium, taking place in San Francisco on February 16-18. Building on more than a decade of leadership in the development of medicines for people diagnosed with GU cancers, Janssen will present data demonstrating its ambition to advance patient-centered treatment through precision medicine, real-world evidence a...
Source: Johnson and Johnson - February 13, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
Breast cancer risk remains elevated 20-30 years after childbirth
<img width="100" src="https://factor.niehs.nih.gov/sites/niehs-factor/files/styles/large/public/2019/1/feature/1-feature-breast-cancer/thumb859874.jpg?itok=CWrYyDmL" /><br /><p>New research shows pregnancy first elevates breast cancer risk, but becomes protective over time.</p>
(read more) (Source: Environmental Factor - NIEHS Newsletter)
Source: Environmental Factor - NIEHS Newsletter - February 3, 2023 Category: Environmental Health Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports good results for 2022 despite decline in demand for COVID-19 products
Group sales grow by 2%1 at constant exchange rates (CER) and 1% in Swiss francs, despite lower COVID-19-related sales in both divisionsPharmaceuticals Division salesincrease by 2%; continued strong growth of newer medicines more than compensating for the impact of biosimilars and lower sales of Actemra/RoActemra (severe COVID-19)Diagnostics Division salesgrow by 3%; ongoing strong momentum in base business (+7%) more than compensating for the continuing decline in the demand for COVID-19 tests in the second half of the yearHighlightsin the fourth quarter of 2022 (incl. January 2023):US approvals ofLunsumio (follicular lymp...
Source: Roche Investor Update - February 2, 2023 Category: Pharmaceuticals Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports good results for 2022 despite decline in demand for COVID-19 products
Basel, 2 February 2023Group sales grow by 2%1 at constant exchange rates (CER) and 1% in Swiss francs, despite lower COVID-19-related sales in both divisionsPharmaceuticals Division salesincrease by 2%; continued strong growth of newer medicines more than compensating for the impact of biosimilars and lower sales of Actemra/RoActemra (severe COVID-19)Diagnostics Division salesgrow by 3%; ongoing strong momentum in base business (+7%) more than compensating for the continuing decline in the demand for COVID-19 tests in the second half of the yearHighlightsin the fourth quarter of 2022 (incl. January 2023):US approvals ofLun...
Source: Roche Media News - February 2, 2023 Category: Pharmaceuticals Source Type: news
Pregnancy After Breast Cancer Is Safe, Landmark Study Says
Initial results from a new study show women who paused protective post-cancer therapies to get pregnant had no increased risk of their cancer coming back. Nearly 3 in 4 women in the study got pregnant, and 64% had a live birth. (Source: WebMD Health)
Source: WebMD Health - January 5, 2023 Category: Consumer Health News Source Type: news
ER+ Breast Cancer Data: SERDs, Pregnancy, and New Targets ER+ Breast Cancer Data: SERDs, Pregnancy, and New Targets
Kathy D. Miller, MD, and Kevin Kalinsky, MD, discuss recent studies important for treating patients with ER-positive disease.Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 3, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news
SABCS: Interrupting Endocrine Therapy Does Not Pose Breast Cancer Recurrence Risk
Findings seen among young women with early - stage, hormone receptor - positive breast cancer desiring pregnancy (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - December 14, 2022 Category: Cancer & Oncology Tags: Gynecology, Oncology, Pharmacy, Conference News, Source Type: news
